Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
about
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusmTOR inhibitors in advanced renal cell carcinomaTargeting the mTOR kinase domain: the second generation of mTOR inhibitorsAkt and autophagy cooperate to promote survival of drug-resistant gliomaThe pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsSequence of treatment in locally advanced and metastatic renal cell carcinomaPI3K and AKT: Unfaithful Partners in CancerOrigins, genetic landscape, and emerging therapies of small cell lung cancerTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsMnk kinase pathway: Cellular functions and biological outcomesUse of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomesWill kinase inhibitors make it as glioblastoma drugs?mTOR kinase inhibitors as potential cancer therapeutic drugsmTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling AxisDrosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate TherapeuticDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerMYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsmTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activationJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesEnhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling PathwaysTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaRegulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signalingUpregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-кB cascade in astrocytic oxygen-glucose deprivationmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktCompensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancerTargeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumorsChronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease.Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells.Enhancing mTOR-targeted cancer therapy.Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancerMaintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
P2860
Q21133610-EC1FFF43-71A9-4F38-A143-685544C9C55BQ24600932-EBF5847A-1156-4616-9BBA-187C46B7E8FFQ24612127-0A330104-8CD7-4B0F-806D-E0CFE1E756DCQ24622194-E5E2C3BB-B58A-4D4B-BC5F-D16A4709C467Q24629677-59477555-9F2E-472E-8E5D-A3A63DE8CA6FQ26740374-E1674101-6B9D-4344-B77C-C2304D83D287Q26773653-481C4D11-0D8A-4F15-AD8A-176DE17879E5Q26781367-704A4CB7-3771-44B3-82D4-5DD94DF06958Q26798218-900A5B0C-0F37-4068-AF16-F4F735F58D28Q26829652-8AD0B8AE-3E6C-4556-A341-8C18421064A9Q26851852-5ED56711-0EEF-4AF3-A127-0B6FFA7E19B6Q26862544-2C6FA1C8-86B6-4827-9719-B0B13A63F5BEQ26865459-E2A1792D-6C09-4A2F-B930-41D035FFECDDQ27009257-5D53E4A8-368A-427A-84F4-01F0B21546FCQ27012684-2AB53D3D-3762-4CBB-BC72-CE1D9158EECDQ27027963-EC561ADD-5E35-4507-B189-F31D23166A01Q27310985-6949CA8C-1769-4EDA-91CE-1EAB6F26501FQ27319935-4BB47AFE-29DF-4A67-BFEA-B9B48360AD05Q27324821-FFC76237-507B-4AA9-8026-7449F1251D52Q27350187-DA85C74E-15E0-450D-89AB-E0F68784D306Q27851707-9223EDB6-F2C5-4BD5-914F-A088693C95C6Q27852528-42413037-74C1-4A59-80FD-8A56253EA90CQ28071388-0DA68C9A-A8B1-4A4E-A9C3-392AB228957AQ28084585-2ED7BD40-6FA0-48C3-A7A3-BFA618F2B1AFQ28382812-DDD0FF8C-A107-4912-8480-77641CC860C4Q28472048-F77204E5-2688-44C4-815A-FB1821C88687Q28475546-89F396F5-985B-4647-A1DE-FF9D2BF85394Q28576235-CD908C59-8E68-467F-AC8C-40D4250B8605Q29547767-C62A1019-23BC-4E16-89BE-3727029CD5B7Q30425261-51A7C05D-E4A9-497B-992A-E773C46A6EA3Q30524134-A5C1B5A4-1514-4BF9-94E9-A37A29AC073AQ30544139-954B73C7-F78A-4105-90C5-2E4F1587D346Q30583249-5EE893CC-200C-4B83-8027-613ECECA311AQ33382236-9EC11EB1-8F40-4147-AB41-A3CD9A805992Q33407185-92DA9FBA-BF35-4A6C-A8E6-58AC62F72556Q33418329-414EC1D1-8247-416C-A353-A315AEEBCA38Q33557066-56741BCC-B479-446E-93BB-DE12B29F0CA0Q33604979-2ED220E0-6F30-4100-86F3-CEF169AD3A31Q33608491-F0C66767-A2D1-4063-AE1D-5C3F406D5566Q33645556-9E7CFDB1-05C6-466D-A076-49E2B81DFBA9
P2860
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@ast
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@en
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@nl
type
label
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@ast
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@en
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@nl
prefLabel
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@ast
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@en
Activation of Akt and eIF4E su ...... arget of rapamycin inhibition.
@nl
P2093
P1433
P1476
Activation of Akt and eIF4E su ...... target of rapamycin inhibition
@en
P2093
Fadlo R Khuri
Shi-Yong Sun
Xuerong Wang
Zhongmei Zhou
P304
P356
10.1158/0008-5472.CAN-05-0917
P407
P577
2005-08-01T00:00:00Z